{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:55Z","timestamp":1787246695848,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01776-0","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:53:45Z","timestamp":1777978425000},"page":"3905-3918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-4418","authenticated-orcid":false,"given":"Merin","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Raftery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-5200","authenticated-orcid":false,"given":"Irina","family":"Pivneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Voegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3460-1544","authenticated-orcid":false,"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"1776_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","author":"T Zuberbier","year":"2026","unstructured":"Zuberbier T, Abdul Hameed Ansari Z, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70210. (online ahead of print).","journal-title":"Allergy"},{"issue":"1","key":"1776_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.","journal-title":"Nat Rev Dis Primers"},{"key":"1776_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13223-020-00459-5","volume":"16","author":"P Stepaniuk","year":"2020","unstructured":"Stepaniuk P, Kan M, Kanani A. Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2020;16:63.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"1776_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bjd.19561","volume":"184","author":"M Gon\u00e7alo","year":"2021","unstructured":"Gon\u00e7alo M, Gim\u00e9nez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226\u201336.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1776_CR5","first-page":"1091","volume":"99","author":"S Goldstein","year":"2019","unstructured":"Goldstein S, Eftekhari S, Mitchell L, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99(12):1091\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1776_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.anai.2015.06.030","volume":"115","author":"J Vietri","year":"2015","unstructured":"Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115(4):306\u201311.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1776_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","volume":"81","author":"S Wertenteil","year":"2019","unstructured":"Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1776_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101081","volume":"18","author":"W Soong","year":"2025","unstructured":"Soong W, Patil D, Rodrigues J, et al. Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States. World Allergy Organ J. 2025;18(8):101081.","journal-title":"World Allergy Organ J"},{"issue":"4","key":"1776_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40257-015-0134-8","volume":"16","author":"MS Broder","year":"2015","unstructured":"Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic\/spontaneous urticaria. Am J Clin Dermatol. 2015;16(4):313\u201321.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1776_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100843","volume":"16","author":"W Soong","year":"2023","unstructured":"Soong W, Patil D, Pivneva I, et al. Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria. World Allergy Organ J. 2023;16(12):100843.","journal-title":"World Allergy Organ J"},{"issue":"7","key":"1776_CR11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jaip.2024.04.016","volume":"12","author":"X Chu","year":"2024","unstructured":"Chu X, Wang J, Ologundudu L, et al. Efficacy and safety of systemic corticosteroids for urticaria: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2024;12(7):1879-89.e8.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1776_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.anai.2011.10.018","volume":"108","author":"JL Zazzali","year":"2012","unstructured":"Zazzali JL, Broder MS, Chang E, Chiu MW, Hogan DJ. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(2):98\u2013102.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1776_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"1776_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2500\/aap.2016.37.3999","volume":"37","author":"D Ledford","year":"2016","unstructured":"Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A. Corticosteroid-related toxicity in patients with chronic idiopathic urticaria\u2013chronic spontaneous urticaria. Allergy Asthma Proc. 2016;37(6):458\u201365.","journal-title":"Allergy Asthma Proc"},{"issue":"7","key":"1776_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","volume":"103","author":"SC Manson","year":"2009","unstructured":"Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975\u201394.","journal-title":"Respir Med"},{"issue":"3","key":"1776_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.anai.2024.12.008","volume":"134","author":"MA Riedl","year":"2025","unstructured":"Riedl MA, Patil D, Rodrigues J, et al. Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria: real-world evidence. Ann Allergy Asthma Immunol. 2025;134(3):324-32.e4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1776_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.anai.2015.02.003","volume":"114","author":"D Cherepanov","year":"2015","unstructured":"Cherepanov D, Raimundo K, Chang E, et al. Validation of an ICD-9-based claims algorithm for identifying patients with chronic idiopathic\/spontaneous urticaria. Ann Allergy Asthma Immunol. 2015;114(5):393\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1776_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40413-018-0193-4","volume":"11","author":"P Kolkhir","year":"2018","unstructured":"Kolkhir P, Pogorelov D, Darlenski R, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11(1):14.","journal-title":"World Allergy Organ J"},{"issue":"3 Suppl.","key":"1776_CR19","doi-asserted-by":"publisher","first-page":"AB247","DOI":"10.1016\/j.jaad.2023.07.990","volume":"89","author":"S Mehlis","year":"2023","unstructured":"Mehlis S, Patil D, Wells M, et al. 44231 Variability in treatment patterns across specialties in the management of chronic spontaneous urticaria (CSU): a real-world survey in the US. J Am Acad Dermatol. 2023;89(3 Suppl.):AB247.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1776_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.anai.2024.06.003","volume":"133","author":"AWL Chu","year":"2024","unstructured":"Chu AWL, Rayner DG, Chu X, et al. Topical corticosteroids for hives and itch (urticaria): systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. 2024;133(4):437-44.e18.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1776_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/all.13556","volume":"74","author":"J Voorham","year":"2019","unstructured":"Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273\u201383.","journal-title":"Allergy"},{"issue":"4","key":"1776_CR22","first-page":"365","volume":"29","author":"SP Huang","year":"2023","unstructured":"Huang SP, DerSarkissian M, Gu YM, et al. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: an evaluation of 12-month economic and clinical burden. J Manag Care Spec Pharm. 2023;29(4):365\u201377.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1776_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317\u201330.","journal-title":"Allergy"},{"issue":"5 Suppl. 1","key":"1776_CR24","first-page":"S10","volume":"131","author":"J Bernstein","year":"2023","unstructured":"Bernstein J, Balp M, McCarthy J, et al. The Urticaria Voices study: antihistamine treatment patterns and patient reported control in chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2023;131(5 Suppl. 1):S10-11.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"1776_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/03007995.2024.2354534","volume":"40","author":"A Seetasith","year":"2024","unstructured":"Seetasith A, Holden M, Hetherington J, et al. Real-world outcomes in patients with chronic spontaneous urticaria receiving omalizumab: insights from a clinical practice survey. Curr Med Res Opin. 2024;40(6):1059\u201366.","journal-title":"Curr Med Res Opin"},{"key":"1776_CR26","unstructured":"Novartis Pharmaceuticals Corporation. RHAPSIDO\u00ae (remibrutinib) prescribing information. 2025. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/rhapsido.pdf. Accessed 18 Feb 2026."},{"key":"1776_CR27","unstructured":"Regeneron Pharmaceuticals Inc. DUPIXENT\u00ae (dupilumab) prescribing information. 2025. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 18 Feb 2026."},{"key":"1776_CR28","unstructured":"ClinicalTrials.gov. A phase 3 study of barzolvolimab in participants with chronic spontaneous urticaria (EMBARQ-CSU1). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06445023. Accessed 18 Feb 2026."},{"key":"1776_CR29","unstructured":"ClinicalTrials.gov. A phase 3 study of barzolvolimab in participants with chronic spontaneous urticaria (CSU) (EMBARQ-CSU2). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06455202. Accessed 18 Feb 2026."},{"issue":"10450","key":"1776_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404.","journal-title":"Lancet"},{"key":"1776_CR31","unstructured":"ClinicalTrials.gov. A study of efficacy and safety of TLL-018 in CSU participants. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06396026. Accessed 18 Feb 2026."},{"issue":"2","key":"1776_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","volume":"6","author":"K Kulthanan","year":"2018","unstructured":"Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586\u201399.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1776_CR33","first-page":"138","volume":"42","author":"M Unsel","year":"2024","unstructured":"Unsel M. Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: real life data. Asian Pac J Allergy Immunol. 2024;42(2):138\u201346.","journal-title":"Asian Pac J Allergy Immunol"}],"updated-by":[{"DOI":"10.1007\/s13555-026-01816-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01776-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:53Z","timestamp":1787243393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01776-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01776-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-026-01816-9","URL":"https:\/\/doi.org\/10.1007\/s13555-026-01816-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gil Yosipovitch is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He has received honoraria as a consultant and\/or advisory board member for AbbVie, Amgen, Arcutis Biotherapeutics, Celldex, Eli Lilly, Escient Pharmaceuticals, Galderma, GSK, Kamari Pharma, Kiniksa Pharmaceuticals, LEO Pharma, Maruho, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Trevi Therapeutics, and CSL Vifor; has received research funding from Celldex, Eli Lilly, Escient Health, Kiniksa Pharmaceuticals, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; and was involved in the patent application for topical acetaminophen. Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, and Tara Raftery are full-time employees of Novartis and may own stock or stock options. Irina Pivneva, Jason Doran, Arthur Voegel, and James Signorovitch are full-time employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Novartis Pharma AG. Marc A. Riedl has received research and\/or consulting support from Astria Therapeutics, Biocryst, Biomarin, Celldex, CSL Behring, Cycle Pharmaceuticals, Grifols, Intellia Therapeutics, Ionis Pharmaceuticals, Kalvista Pharmaceuticals, Novartis, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, and Takeda Pharmaceuticals.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a noninterventional study that used a de-identified administrative claims database, ethical approval and consent to participate were not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}